News

Zetagen Therapeutics Advances Cancer Treatment with ZetaMAST™

Zetagen Therapeutics Advances Cancer Treatment with ZetaMAST™

Innovative Cancer Treatments Revealed by Zetagen Therapeutics

In a recent announcement, Zetagen Therapeutics, Inc. showcased exciting advancements regarding their drug candidate, ZetaMAST™ (Zeta-MBC-005). This clinical-stage biopharmaceutical company is on a mission to revolutionize treatment methodologies tailored for patients battling metastatic and primary breast cancer. Focusing on reducing side effects while aiming to enhance survival rates, Zetagen has reported noteworthy findings from their latest study involving the dosing of ZetaMAST™.

Positive In-vivo Results for ZetaMAST™

Zetagen's research involved detailed examination of ZetaMAST™'s efficacy in an in-vivo model, where they tested various concentrations of the drug. The findings were promising, revealing that two specific concentrations of Zeta-MBC-005 exhibited significantly superior effectiveness in tumor burden reduction compared to the traditional control drug Doxorubicin. This is an important step in the fight against breast cancer, especially for those with liver metastases.

Expert Insights on ZetaMAST™

Dr. Debasish Tripathy, a noted Professor at The University of Texas MD Anderson Cancer Center, expressed optimism regarding ZetaMAST™. He highlighted the potential of local therapies to alleviate symptoms for liver metastasis but noted their limitations in extending overall survival. His insights underline the importance of ZetaMAST™ as an innovative approach that offers systemic biological effects in preclinical trials, specifically targeting liver metastases.

Clinical Trials on the Horizon

Furthermore, Dr. Bryan S. Margulies, CSO of Zetagen, indicated enthusiasm for the upcoming Phase 1b clinical trials for ZetaMAST™. The hope is that these trials will lead to significant benefits for patients dealing with metastatic breast cancer in the liver, further showcasing Zetagen's commitment to pushing boundaries in cancer therapy.

Understanding ZetaMAST™

At its core, ZetaMAST™ (Zeta-MBC-005) is a cleverly engineered injectable drug-eluting hydrogel carrier. It is designed to facilitate controlled release of two small molecules synergistically aimed at treating multifocal unresectable liver metastases linked to breast cancer. This targeted approach aims not just to manage symptoms but to drive survival rates upward — a crucial goal in the treatment of advanced cancer.

About Zetagen Therapeutics

Zetagen Therapeutics was established with a clear focus: to pioneer and bring to market innovative therapies that purposefully deliver tumoricidal treatments for metastatic and primary breast cancer. Since its inception in 2015, the company has embraced a forward-thinking approach, characterized by minimizing side effects while potentially enhancing survival outcomes for patients.

The dedication of Zetagen has been recognized by the US Food and Drug Administration (FDA), which has awarded the company multiple Breakthrough Designations for their innovative therapies, including ZetaMet™ (Zeta-BC-003).

Clinical Successes and Ongoing Trials

Zetagen has achieved considerable success under the FDA’s Expanded Access (Compassionate Use) program for ZetaMet™ (Zeta-BC-003), treating several patients whose remarkable results have been documented in various peer-reviewed journals. Currently, Zetagen is enrolling participants for the Phase IIa clinical trial of ZetaMet™ (Zeta-BC-003), specifically targeting patients with metastatic breast cancer affecting the spine.

Future Endeavors and Events

As Zetagen Therapeutics continues on its path of innovation, it is set to participate in key events like the San Antonio Breast Cancer Symposium (SABCS) and the JP Morgan Healthcare Conference. These events present opportunities to share their breakthroughs with a broader audience, engage with fellow researchers, and inform stakeholders about their advancements.

Frequently Asked Questions

What is ZetaMAST™?

ZetaMAST™ (Zeta-MBC-005) is a drug designed to treat multifocal unresectable liver metastases from breast cancer through a controlled release system.

What were the results of the in-vivo study?

The study showed that specific concentrations of ZetaMAST™ effectively reduced tumor burden and improved survival compared to standard Doxorubicin treatment.

Who leads Zetagen Therapeutics?

Zetagen is led by a team of skilled professionals, including Bryan S. Margulies, who is the Chief Scientific Officer, contributing to its innovative research and development.

What FDA recognitions has Zetagen received?

Zetagen has received several Breakthrough Designations from the FDA for its drugs, which highlights the potential of their therapies to address unmet medical needs.

What are the upcoming events for Zetagen?

Zetagen will participate in significant conferences, including the San Antonio Breast Cancer Symposium and the JP Morgan Healthcare Conference, to showcase its advancements in cancer treatment.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Accuray Finishes Key Deal, Resetting Financial Trajectory

Updated Category News Views 136

Accuray Secures the Deal, But Is the Future Bright? Every now and then in the investing world, a company pulls off a maneuver that you wish you’d thought of first. Today, folks, it's Accuray's turn. They've just wrapped up a monstrous transaction with TCW – their primary lender and shareholder – that has them feeling optimistic about the road ahead. Bold Moves to...

Continue Reading
First Horizon's $25M Bet: New Center Transforms Houston

Updated Category News Views 187

New Markets Tax Credits: A Game Changer First things first, if you're thinking this is some typical charitable write-off, think again. First Horizon Bank (NYSE: FHN) is deep in the mix of something pretty transformative in the world of finance and community support. They're not just throwing money at a problem and hoping it sticks. Nope, we're talking real strategy with a...

Continue Reading
PenFed Fuels Aggie Spirit with Blackout Game Activation

Updated Category News Views 196

A Different Kind of Game Day Experience Ah, there's nothing quite like the vibrancy of a Texas A&M game day, especially when it's a blackout event. On November 14, fans aren't just getting the good old college football thrills; they're diving headfirst into an extravaganza, courtesy of PenFed Credit Union. You might know them as the go-to credit union for military folks,...

Continue Reading
Thanksgiving in Outer Banks: Unique Traditions Await

Updated Category News Views 115

Thanksgiving Plans Off the Beaten Path Thanksgiving in the Outer Banks isn't just another holiday; it's a whole different ball game. Imagine trading in the usual family couch-potato marathon for a beachside gathering, where the sand replaces the snow, and coastal seafood joins the turkey on your dinner table. If you've been teetering on the edge of making plans, this...

Continue Reading
ACME's AI Innovation Shakes Up Filmmaking Scene

Updated Category News Views 87

The Game-Changer in Virtual Production You ever hear about the Grey Box™ phenomenon? Sounds like a sci-fi gizmo, right? Turns out, it's the real deal and ACME Media's been riding this revolutionary wave straight to the top of the film industry ladder. Their approach with this AI-driven gizmo isn't just about cutting-edge tech wizardry—it's reimagining how we shoot...

Continue Reading
Surprising Week on Wall Street: Chips Drive Gains

Updated Category News Views 163

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 139

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading
Terra Kaffe's Big Win with Oprah's Endorsement

Updated Category News Views 109

Terra Kaffe Hits the Jackpot with Oprah Sometimes, destiny has a way of handing out golden tickets, and for Terra Kaffe, receiving a nod from Oprah Winfrey's revered list of Favorite Things for 2026 is nothing short of that. I mean, you can't underestimate the pull Mrs. O has. Her endorsement isn’t just another celebrity pat-on-the-back, it’s a megaphone blaring...

Continue Reading
Shorenstein Expands in Dallas: Strategic Play or Risk?

Updated Category News Views 127

Shorenstein's recent acquisition of International Plaza 3 isn't just about adding another high-rise to their portfolio; it's a stake in the ground, a doubling down on the Dallas real estate market. With its aim sharply set on the Lower Tollway submarket, Shorenstein is showing confidence, but the big question remains—are they spot on or walking the razor's edge?...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 60

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading

Top 5 Most Recently Viewed Articles

The Brattle Group Enhances Services with New Principal

Updated Category News Views 168

The Brattle Group Enhances Services with New Principal The Brattle Group is pleased to announce the addition of Hans Weemaes as a Principal in its Financial Services & Markets and Regulatory Investigations & Enforcement practices. With an impressive background as a former economist for a federal treasury, Mr. Weemaes carries over 20 years of extensive experience in...

Continue Reading
Lumen and AWS Unite to Advance Generative AI Through Networks

Updated Category News Views 263

Lumen and AWS Join Forces in Generative AI Development Lumen Technologies (NYSE: LUMN) has announced a strategic collaboration with Amazon Web Services (AWS), an Amazon.com company (NASDAQ: AMZN), aiming to enhance network operations and delivery capabilities. This partnership is set against the backdrop of expanding AI-driven services that demand efficient and robust...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 46

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Modernization: Strengthening Ties Between China and Africa

Updated Category News Views 64

Modernization: Strengthening Ties Between China and Africa Recently, China Everything released an engaging short video titled "A shared path to modernization." This video highlights the successful collaboration between China and Africa, showcasing the strong friendship that has developed between the people of these two regions. The Unity of Aspirations As the largest...

Continue Reading
Okeanis Eco Tankers Announces Dividend Details for Shareholders

Updated Category News Views 129

Okeanis Eco Tankers Declares Dividend for Common Shares Okeanis Eco Tankers Corp. (NYSE: ECO / OSE: OET) has announced a significant dividend for its shareholders. The board of directors has officially declared a dividend on its common shares, representing a fruitful opportunity for investors as they participate in the company's success. This dividend is a reflection of...

Continue Reading